Highlights of This Issue 5341

SPECIAL FEATURES

CCR Translations
5343 Hormone Whodunit: Clues for Solving the Case of Intratumor Androgen Production
Karen E. Knudsen
See related article, p. 5547

5346 Matching Wits with Melanoma Brain Metastases: From Biology to Therapeutics
Hussein Tawbi
See related article, p. 5537

CCR New Strategies
5349 New Strategies in Advanced Cervical Cancer: From Angiogenesis Blockade to Immunotherapy
Krishnansu S. Tewari and Bradley J. Monk

CCR Perspectives in Drug Approval
5359 First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer
Laleh Amiri-Kordestani, Suparna Wedam, Lijun Zhang, Shenghui Tang, Amy Tilley, Anna Ibrahim, Robert Justice, Richard Pazdur, and Patricia Cortazar

CCR Drug Updates
5365 Ibrutinib for the Treatment of Mantle Cell Lymphoma
Alex F. Herrera and Eric D. Jacobsen

Molecular Pathways
5372 Molecular Pathways: Epigenetic Modulation of Wnt–Glycogen Synthase Kinase-3 Signaling to Target Human Cancer Stem Cells
Yannick D. Benoit, Borhane Guezguez, Allison L. Boyd, and Mickie Bhatia

5379 Molecular Pathways: Intercellular PTEN and the Potential of PTEN Restoration Therapy
Benjamin D. Hopkins and Ramon E. Parsons

Review
5384 Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence
Andreas R. de Basi, Jonathan Villena-Vargas, and Prasad S. Adusumilli

CANCER THERAPY: CLINICAL
5392 A Phase I/II Trial of Belinostat in Combination with Cisplatin, Doxorubicin, and Cyclophosphamide in Thymic Epithelial Tumors: A Clinical and Translational Study
Anish Thomas, Arun Rajan, Eva Szabo, Yusuke Tomita, Corey A. Carter, Barbara Scepura, Ariel Lopez-Chavez, Min-Jung Lee, Christophe E. Redon, Ari Frosch, Cody J. Peer, Yuanbin Chen, Richard Piekarz, Seth M. Steinberg, Jane B. Trepel, William D. Figg, David S. Schrump, and Giuseppe Giaccone

PERSONALIZED MEDICINE AND IMAGING
5403 Qualification of a Noninvasive Magnetic Resonance Imaging Biomarker to Assess Tumor Oxygenation
Florence Colliez, Marie-Aline Neveu, Julie Magat, Thanh Trang Cao Pham, Bernard Galvez, and Bénédicte F. Jordan

CANCER THERAPY: PRECLINICAL
5412 mTOR Inhibitors Induce Cell-Cycle Arrest and Inhibit Tumor Growth in Epstein–Barr Virus–Associated T and Natural Killer Cell Lymphoma Cells
Jun-ichi Kawada, Yoshinori Ito, Seiko Iwata, Michio Suzuki, Yoshihiko Kawano, Tetsuhiro Kanazawa, Mohammed Nure Alam Siddiquey, and Hiroshi Kimura
Targeting the Oncogenic MUC1-C Protein Inhibits Mutant EGFR-Mediated Signaling and Survival in Non–Small Cell Lung Cancer Cells
Akriti Kharbanda, Hasan Rajabi, Caining Jin, Jeremy Tchaicha, Eiki Kikuchi, Kwok-Kin Wong, and Donald Kufe

Deoxycytidine Kinase Expression Underpins Response to Gemcitabine in Bladder Cancer
Martin Kerr, Helen E. Scott, Blaz Groselj, Michael R.L. Stratford, Katalin Karaszi, Naomi L. Sharma, and Anne E. Killie

Inhibition of NANOG/NANOGP8 Downregulates MCL-1 in Colorectal Cancer Cells and Enhances the Therapeutic Efficacy of BH3 Mimetics
Abid R. Mattoo, Jingyu Zhang, Luis A. Espinoza, and J. Milburn Jessup

Toll-like Receptor Agonist Imiquimod Facilitates Antigen-Specific CD8⁺ T-cell Accumulation in the Genital Tract Leading to Tumor Control through IFNγ
Ruey-Shyang Soong, Liwen Song, Janson Trieu, Jayne Knoff, Liangmei He, Ya-Chea Tsai, Warner Huh, Yung-Nien Chang, Wen-Fang Cheng, Richard B.S. Roden, T.-C. Wu, Cornelia L. Trimble, and Chien-Fu Hung

The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness

Upregulation of IGF1R by Mutant RAS in Leukemia and Potentiation of RAS Signaling Inhibitors by Small-Molecule Inhibition of IGF1R
Ellen Weisberg, Atsushi Nonami, Zhao Chen, Erik Nelson, Yongfei Chen, Feiyang Liu, Haeyeon Cho, Jianming Zhang, Martin Sattler, Constantine Mitsiades, Kwok-Kin Wong, Qingsong Liu, Nathanael S. Gray, and James D. Griffin

Preclinical Activity of the Liposomal Cisplatin Lipoplatin in Ovarian Cancer
Naiké Casagrande, Marta Celegato, Cinzia Borghese, Maurizio Mongiat, Alfonso Colombatti, and Donatella Aldinucci

Deficient Cutaneous Antibacterial Competence in Cutaneous T-Cell Lymphomas: Role of Th2-Mediated Biased Th17 Function

Activating FGFR2–RAS–BRAF Mutations in Ameloblastoma
Noah A. Brown, Delphine Rolland, Jonathan B. McHugh, Helmut C. Weigelin, Lili Zhao, Megan S. Lim, Kojo S.J. Elenitoba-Johnson, and Bryan L. Betz

Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIIB/C Melanoma Patients with BRAFV600E Mutations

Molecular Profiling of Patient-Matched Brain and Extracranial Melanoma Metastases Implicates the PI3K Pathway as a Therapeutic Target
See related commentary, p. 5346
Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer
Matthew Fankhauser, Yuen Tan, Geoff Macintyre, Izhak Haviv, Matthew K.H. Hong, Anne Nguyen, John S. Pedersen, Anthony J. Costello, Christopher M. Hovens, and Niall M. Corcoran
See related commentary, p. 5343

Galectin-1 Mediates Radiation-Related Lymphopenia and Attenuates NSCLC Radiation Response
Peiwen Kuo, Scott V. Bratman, David B. Shultz, Rie von Eyben, Cato Chan, Ziwei Wang, Carmen Say, Aparna Gupta, Bill W. Loo Jr, Amato J. Giaccia, Albert C. Koong, Maximilian Diehn, and Quynh-Thu Le

ABOUT THE COVER
The cover shows immunohistochemical sections of xenografts derived from gemcitabine-sensitive CAL29 bladder cancer cells. Sections were stained for Dck, and nuclear positivity was quantified using Aperio scanscope software, using the Nuclear y9 algorithm. For details, see the article by Kerr and colleagues on page 5435 of this issue.